Hanson & Doremus Investment Management Purchases 2,180 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Hanson & Doremus Investment Management boosted its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 28.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,775 shares of the medical research company's stock after purchasing an additional 2,180 shares during the period. Hanson & Doremus Investment Management's holdings in IQVIA were worth $1,921,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in IQV. Simplify Asset Management Inc. increased its position in IQVIA by 67.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company's stock valued at $2,284,000 after acquiring an additional 3,894 shares during the period. Nordea Investment Management AB increased its holdings in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after purchasing an additional 452,029 shares during the period. Smith Group Asset Management LLC acquired a new position in IQVIA during the 4th quarter worth about $1,616,000. Versor Investments LP bought a new stake in shares of IQVIA in the 3rd quarter valued at about $1,328,000. Finally, Fifth Third Bancorp increased its stake in shares of IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock valued at $2,590,000 after buying an additional 1,521 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on IQV shares. Robert W. Baird decreased their target price on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a research report on Tuesday, January 21st. Truist Financial dropped their target price on shares of IQVIA from $265.00 to $261.00 and set a "buy" rating on the stock in a report on Thursday, December 12th. BTIG Research decreased their price target on IQVIA from $290.00 to $260.00 and set a "buy" rating for the company in a report on Friday, November 1st. Evercore ISI cut their target price on IQVIA from $270.00 to $265.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 8th. Finally, The Goldman Sachs Group lowered their target price on IQVIA from $280.00 to $250.00 and set a "buy" rating for the company in a report on Friday, November 1st. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $255.71.

IQVIA Price Performance

IQVIA stock traded up $3.32 during midday trading on Thursday, hitting $201.39. 991,775 shares of the company's stock were exchanged, compared to its average volume of 1,340,929. The stock has a 50-day moving average price of $200.34 and a two-hundred day moving average price of $220.78. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a market cap of $36.55 billion, a P/E ratio of 26.43, a PEG ratio of 2.14 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.